#1477 🔬Zasocitinib (TYK-2i) shows promise in phase IIb RCT ➡️n=290, randomised to PBO, 5/15/30mg gps 💥30mg group 📉 Rapid skin improvement @ Wk 2 ➡️Wk 12 PASI:~2X placebo (-2.5;p=0.004) 🛟Well tolerated ⬆️MDA (28 v. 12.5% p<0.05) promise for other PsA domains #ACR @RheumNow https://t.co/5GusMlVkQ4

• https://x.com/CaoilfhionnMD/status/1858180043656073432/photo/1

Exciting early data for new highly selective TYK2i zasocitinib Improved PASI skin scores (though not as much as IL23i...) Funky skin-related adverse events at higher doses, not sure what to make of that? #ACR24 @rheumnow Abstr#1477 https://t.co/CtOFsoHdBh

• https://x.com/EBRheum/status/1858180043886764484/photo/1
• https://x.com/EBRheum/status/1858180043886764484/photo/1

T2T approaches in early PsA: -STAMP trial (open label, multicenter RCT) eval early SEC (300mg+ MTX15+ 80mg steroid injection) vs SoC (MTX25+80mg steroid injection) -At week 12, 38% pts on SEC vs 17% on SoC achieved ACR50. Also did better on MDA & PASI. -No significant… https://t.co/MflI3d0FqV https://t.co/RjnzeaTyQK

• https://x.com/i/web/status/1858178289262813384
• https://x.com/AdelaCastro222/status/1858178289262813384/photo/1
• https://x.com/AdelaCastro222/status/1858178289262813384/photo/1

How do you treat a flare of SLE with steroids? @RheumNow #ACR24

Petri: 5 mg prednisone or less is our standard for lupus control EULAR 23 recs - early addition of immunosuppressant and/or biologics instead to prevent steroids @RheumNow #ACR24 @jhrheumatology https://t.co/jhxEeboPu5

• https://x.com/ericdeinmd/status/1858178495269974066/photo/1
• https://x.com/ericdeinmd/status/1858178495269974066/photo/1

RheumNow’s expanded coverage of the #ACR24 meeting is sponsored in part by Bristol Myers Squibb and UCB. All content is chosen by RheumNow & its faculty

New agent on the block: Bimekizumab IL-17A/F inhibitor Promising clinical data in SpA - what about imaging findings? Dramatic reductions in MRI activity at SI joints seen in BKZ pt, esp when compared to trajectory of PBO pt before cross-over @RheumNow #ACR24 Abst #1757 https://t.co/ACLJx5XkyN

• https://x.com/Dr_Brian_MD/status/1858168067844383139/photo/1

At "Envisioning a Steroid Free Future" talk Angelo Gaffo at the mic: "Are there any situations you would do induction therapy for AAV without steroid?" John Stone: [pause] "No." 😄 #ACR24 @RheumNow

#1462 🔬Rx persistence in PsA; Guselkumab (GUS) v. IL17Ai 💡 GUS (n=910) persistence @ 12 months (67%) almost 2X IL-17Ai (n=2743) (50%) ⏳ Median time to discontinuation: GUS not reached v 12.3 months for IL-17Ai. 🔴Durable therapy ❓better outcomes #ACR @RheumNow https://t.co/LfA3WygNVq

• https://x.com/CaoilfhionnMD/status/1858177527115608457/photo/1

Reset the bar for remission (off steroids)!! Session #17S19 3% higher risk of organ damage for each 1mg of pred Remission possible in rheum with lower dose GC regimen and faster taper #GCStewardship #ACR24 @RheumNow @BethIWallace

Single centre experience of belimumab at @GSTTnhs @RheumNow #ACR24 https://t.co/c4jlEPRwen

• https://twitter.com/sahilja09303150/status/1858168844587598111

In case you needed more encouragement for recombinant zoster vaccination in RA patients: it prevents herpes zoster episodes, in the real world. RA pts in KP system n=1926 vaccinated matched 1:3 with non-vaccinated - HZ reduced 60% - PHN reduced 88% #ACR24 ABST0977 @RheumNow https://t.co/BryBrlv9K5

• https://x.com/drdavidliew/status/1858177833232998569/photo/1

Petri on Steroids in SLE Steroid-related organ damage presents later - organ damage is higher in African-Americans Dose response for prednisone and CVD risk Each 1 mg prednisone = 3% increase risk in organ damage! #ACR24 @jhrheumatology @RheumNow https://t.co/00S1mxrXJp

• https://x.com/ericdeinmd/status/1858177175750349255/photo/1
• https://x.com/ericdeinmd/status/1858177175750349255/photo/1

Appreciate the conversation with Dr Ana-Maria Orbai @jhrheumatology on abstract#0600 on bimekizumab PRO data https://t.co/86J4HWKeIv @RheumNow #ACR24 https://t.co/QYqj5rKHIH

• Bimekizumab in PsA Showed Sustained Reductions in Disease Impact
• https://twitter.com/ericdeinmd/status/1857849021110354277

A systematic review reveals significant sex-related differences in efficacy and safety outcomes in axial spondyloarthritis (axSpA) trials. Males show higher response rates to advanced therapies compared to females. Out of 79 RCTs, only a fraction reported sex-disaggregated data.… https://t.co/dkMRK4ZYHF

• https://x.com/i/web/status/1858166957427597483